Assessment of Treatment Response in Hepatocellular Carcinoma: A Review of the Literature

Maida, Marcello; Brancatelli, Giuseppe; Genco, Chiara; Alessi, Nicola; Genova, Claudio; Romano, Piero; Raineri, Santi Maurizio; Giarratano, A; Midiri, Massimo; Cammà, Calogero

doi:10.2217/fon.13.33

Cited by 9 publications

(6 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome these limitations, the EASL and mRECIST criteria have been suggested to be a better way of assessing tumor response in HCC patients. Several studies, recently reviewed [ 28 ], demonstrated their superiority over conventional criteria. The evaluation of tumour viability, represents the most relevant change in EASL/mRECIST criteria compared to traditional WHO/RECIST.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

BackgroundThe European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking.AimTo conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival.MethodsA comprehensive search of the literature was performed in electronic databases EMBASE, MEDLINE, COCHRANE LIBRARY, ASCO conferences and EASL conferences up to June 10, 2014. Our overall search strategy included terms for HCC, mRECIST, and EASL. Loco-regional procedures included transarterial embolization (TAE), transarterial chemoembolization (TACE) and cryoablation. Inter-method agreement between EASL and mRECIST was assessed using the k coefficient. For each criteria, overall survival was described in responders vs. non-responders patients, considering all target lesions response.ResultsAmong 18 initially found publications, 7 reports including 1357 patients were considered eligible. All studies were published as full-text articles. Proportion of responders according to mRECIST and EASL criteria was 62.4% and 61.3%, respectively. In the pooled population, 1286 agreements were observed between the two methods (kappa statistics 0.928, 95% confidence interval 0.912–0.944). HR for overall survival (responders versus non responders) according to mRECIST and EASL was 0.39 (95% confidence interval 0.26–0.61, p<0.0001) and 0.38 (95% confidence interval 0.24–0.61, p<0.0001), respectively.ConclusionIn this literature-based meta-analysis, mRECIST and EASL criteria showed very good concordance in HCC patients undergoing loco-regional treatments. Objective response according to both criteria confirms a strong prognostic value in terms of overall survival. This prognostic value appears to be very similar between the two criteria.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[16] So, complete response is a relevant surrogate end-point that should be planned and carefully assessed by multiphasic CT or MR scan in all patients who undergo RFA. [8], [19].…”

Section: Discussionmentioning

confidence: 99%

Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response

et al. 2013

Self Cite

View full text Add to dashboard Cite

BackgroundRadio-frequency ablation (RFA) has been employed in the treatment of Barcelona Clinic Liver Cancer (BCLC) early stage hepatocellular carcinoma (HCC) as curative treatments.AimTo assess the effectiveness and the safety of RFA in patients with early HCC and compensated cirrhosis.MethodsA cohort of 151 consecutive patients with early stage HCC (122 Child-Pugh class A and 29 class B patients) treated with RFA were enrolled. Clinical, laboratory and radiological follow-up data were collected from the time of first RFA.A single lesion was observed in 113/151 (74.8%), two lesions in 32/151 (21.2%), and three lesions in 6/151 (4%) of patients.ResultsThe overall survival rates were 94%, 80%, 64%, 49%, and 41% at 12, 24, 36, 48 and 60 months, respectively. Complete response (CR) at 1 month (p<0.0001) and serum albumin levels (p = 0.0004) were the only variables indipendently linked to survival by multivariate Cox model. By multivariate analysis, tumor size (p = 0.01) is the only variable associated with an increased likehood of CR.The proportion of major complications after treatment was 4%.ConclusionsRFA is safe and effective for managing HCC with cirrhosis, especially for patients with HCC ≤3 cm and higher baseline albumin levels. Complete response after RFA significantly increases survival.

show abstract

“…In most cases, liver cancer patients are already in an advanced disease stage upon diagnosis, which limited the efficacy of radiotherapy and chemotherapy [5,6]. Although rapid development and wide application of imaging technology, pathology and molecular genetics have benefited HCC patients, death rates are still increasing rapidly for liver cancers [7][8][9][10][11]. Therefore, progressive fights against cancers need consistent clinical and basic research to improve treatment outcome and benefit survival.…”

Section: Introductionsmentioning

confidence: 99%

NEDD4 promotes cell growth and motility in hepatocellular carcinoma

Zheng

et al. 2018

Cell Cycle

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death worldwide. In China, the situation is even worse as cancer incidence and mortality continue to increase rapidly. Although tremendous progress has been made toward HCC treatments, the benefits for liver cancer patients are still limited. Therefore, it is necessary to identify and develop novel therapeutic methods. Neuronally expressed developmentally downregulated 4 (NEDD4), an E3 ubiquitin ligase, plays a critical role in the development and progression of various types of human cancers. In our study, NEDD4 acts as an oncoprotein in both QGY7703 and SMMC7721 liver cancer cell lines. We found that depletion of NEDD4 by siRNA transfection led to inhibition of cell growth, invasion and migration, and promotion of apoptosis. In contrast, overexpression of NEDD4 via plasmid transfection resulted in facilitated cell proliferation, invasion and migration, and decreased apoptosis. Importantly, we observed that tumor suppressor LATS1, also a core component of Hippo pathway, was negatively regulated by NEDD4 in liver cancer cells. Our findings suggested that NEDD4 may be involved in the HCC progression via regulating LATS1 associated signaling pathway. Therefore, targeting NEDD4-LATS1 signaling could be a potential therapeutic option for HCC treatment.

show abstract

Assessment of Treatment Response in Hepatocellular Carcinoma: A Review of the Literature

Cited by 9 publications

References 60 publications

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis

Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response

NEDD4 promotes cell growth and motility in hepatocellular carcinoma

Contact Info

Product

Resources

About